



DILIsym Services

S+ A SIMULATIONS PLUS COMPANY

Please note: this presentation, including questions from the audience, is being recorded

DILIsym Review Session 27:

IVIVE in DILIsym Using GastroPlus/ADMET Predictor

November 8, 2018

Kyunghee Yang, Christina Battista

** DILIsym®, NAFLDsym®, and MITOsym® are registered trademarks and SimPops™ and SimCohorts™ are trademarks of DILIsym® Services Inc. for computer modeling software and for consulting services.*

CONFIDENTIAL



DILIsym Review Session Agenda

- Introduction
- IVIVE in DILIsym using ADMET Predictor
- IVIVE in DILIsym using GastroPlus
- A case study: IVIVE using GastroPlus & DILIsym to predict liver safety of investigational drugs



DILIsym is a Quantitative Systems Toxicology Platform That Predicts *In Vivo* Liver Safety Using *In Vitro*/Preclinical Data

- What is IVIVE?
 - Represents “In Vitro-In Vivo Extrapolation”
 - Method of applying the results from *in vitro* experiments to predict *in vivo* outcomes
 - Reduces animal studies and improve predictivity of human outcomes
 - IVIVE can range from very simple, static equations, all the way to sophisticated dynamic models that combine PBPK and systems pharmacology/toxicology models
- IVIVE in DILIsym
 - PBPK sub-model predicts *in vivo* systemic/hepatic exposure of drugs/metabolites using *in vitro* data
 - Integrates predicted exposure and *in vitro* mechanistic toxicity data to predict *in vivo* liver safety of drugs/metabolites
 - Training videos available at www.DILIsymHelp.com to outline IVIVE process for toxicity data


DILIsymServices

S+ A SIMULATIONS PLUS COMPANY


CONFIDENTIAL



Saying “I do” to the QSAR / PBPK / QST marriage...



Permeability,
solubility vs. pH,
pKa(s),
logD vs. pH,
Fup,
blood:plasma
ratio, tissue Kps,
CLint, CLfilt



Local & systemic
exposure, drug
distribution,
parent and
metabolite
levels,
patient
variability



Quantitative Structure Activity Relationships
(QSAR)

ADMET Predictor™

Physiologically-Based Pharmacokinetics
(PBPK)

GastroPlus™

Quantitative Systems Pharmacology/Toxicology
(QSP/QST)

DILIsym®

DILIsym Services

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



DILIsym Utilizes Various Data Types to Inform Decisions

Exposure Data

PBPK Modeling

- **Compound Properties**
 - Tissue partition coefficients
- **Tissue penetration studies**
 - Liver to blood ratio
- **Pharmacokinetic data**
 - Absorption, extra-hepatic clearance, metabolites
- **in vitro data**
 - Metabolite synthesis, active uptake

In vitro Mechanistic DILI Data

Assays performed to determine quantitative aspects of DILI mechanisms

- **Oxidative stress**
 - Direct and reactive metabolite-mediated
- **Mitochondrial toxicity**
 - ETC inhibition
 - Uncoupling
- **Bile acid transporter inhibition**
 - BSEP, MRP3 and 4, NTCP
- **Bilirubin transport/metabolism**
 - OATP1B1, OATP1B3, UGT1A1, MRP2, MRP3



Modeling & Simulation

Simulations and Assays inform:

- Prediction of DILI risk
- Participating DILI mechanisms
- Characteristics of patients at risk for DILI
- Drug dosing paradigms
- DILI monitoring strategies



Clinical Data

- Dosing Protocols, fasting/fed state, meal times
- Anthropometric data
 - Body weight, age, ethnicity
- Pharmacokinetic data
 - Absorption, extra-hepatic clearance, metabolites

DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



DILIsym Utilizes Various Data Types to Inform Decisions

Exposure Data

PBPK Modeling

- **Compound Properties**
 - Tissue partition coefficients
- **Tissue penetration studies**
 - Liver to blood ratio
- **Pharmacokinetic data**
 - Absorption, extra-hepatic clearance, metabolites
- **in vitro data**
 - Metabolite synthesis, active uptake

**ADMET Predictor,
GastroPlus**

In vitro Mechanistic DILI Data

Assays performed to determine quantitative aspects of DILI mechanisms

- **Oxidative stress**
 - Direct effects on cytochrome-mediated metabolism
- **Mitochondrial toxicity**
 - ER stress
 - Uncoupling
- **Bile acid transporter inhibition**
 - BSEP, MRP3 and 4, NTCP
- **Bilirubin transport inhibition**
 - OATP1B1, OATP1B3, UGT1A1, MRP2, MRP3

**ADMET Predictor,
MembranePlus**

ADMET Predictor



Modeling & Simulation

Simulations and Assays inform:

- Prediction of DILI risk
- Participating DILI mechanisms
- Characteristics of patients at risk for DILI
- Drug dosing paradigms
- DILI monitoring strategies



Clinical Data

- Dosing Protocols, fasting/fed state, meal times
- Anthropometric data
 - Body weight, age, ethnicity
- Pharmacokinetic data
 - Absorption, extra-hepatic clearance, metabolites

DILIsym Services

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL




DILIsym Review Session Agenda

- Introduction
- IVIVE in DILIsym using ADMET Predictor
- IVIVE in DILIsym using GastroPlus
- A case study: IVIVE using GastroPlus & DILIsym to predict liver safety of an investigational drug




ADMET Predictor Can Predict Input Parameters for DILIsym PBPK Sub-Model From Structure



Permeability,
solubility vs. pH,
pKa(s),
logD vs. pH,
Fup,
blood:plasma
ratio, tissue Kps,
CLint, CLfilt

Quantitative Structure Activity Relationships
(QSAR)

ADMET Predictor™



Physiologically-Based Pharmacokinetics
(PBPK)

GastroPlus™

Local & systemic
exposure, drug
distribution,
parent and
metabolite
levels,
patient
variability

Quantitative Systems Pharmacology/Toxicology
(QSP/QST)

DILIsym®



DILIsym Services

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



DILIsym PBPK Sub-Model Input Parameters Fall into Several Main Categories

- Physicochemical properties
 - Acidic/basic pKa

Make sure to select relevant subgroup (e.g., Compound W, X, Y...)

DILIsym Parameter Customization

Group: Drug Subgroup: Compound W PBPK

Variable	Value	Units	This parameter
Compound W molecular weight	1.0000e-03 g/mol		This parameter
Compound W acid base switch	1 switch		This parameter
Compound W pKa 1 or pKa base (for zwitter ion)	0 dimensionless		This parameter
Compound W pKa 2 or pKa acid (for zwitter ion)	0 dimensionless		This parameter
Compound W renal clearance	0 mL/hour/kg*0.75		This parameter
k(diss) - Compound W	12 1/hour		This parameter
k(ge) - Compound W	12 1/hour		This parameter
k(ab) - Compound W	5 1/hour		This parameter
Compound W absorption from gut Vmax	0 1/hour		This parameter
Compound W absorption from gut Km	1.0000e+10 mg		This parameter
Compound W rate of elimination in feces	0 1/hour		This parameter
k(ab,IP dose) - Compound W	12 1/hour		This parameter
k(IV) - Compound W	60 1/hour		This parameter

Convert Panel View Compare (mat) Save w/ Custom Compare (xls) Cancel Changes Save



DILIsym PBPK Sub-Model Input Parameters Fall into Several Main Categories

- Physicochemical properties
 - Acidic/basic pKa
- Absorption
 - Saturable and linear models

DILIsym Parameter Customization

Group: Drug Subgroup: Compound W PBPK

Variable	Value	Units	Parameter
Compound W pKa 2 or pKa acid (for zwitter ion)	0	dimensionless	This parameter
Compound W renal clearance	0	mL/hour/kg ^{0.75}	This parameter
k(diss) - Compound W	12	1/hour	This parameter
k(ge) - Compound W	12	1/hour	This parameter
k(ab) - Compound W	5	1/hour	This parameter
Compound W absorption from gut Vmax	0	1/hour	This parameter
Compound W absorption from gut Km	1.0000e+10	mg	This parameter
Compound W rate of elimination in feces	0	1/hour	This parameter
k(ab,IP dose) - Compound W	12	1/hour	This parameter
k(IV) - Compound W	60	1/hour	This parameter
Compound W fraction unbound in enterocytes (for meta...	1	dimensionless	This parameter
Compound W gut efflux Vmax	0	ug/hour/kg ^{0.75}	This parameter
Compound W gut efflux Km	1.0000e+10	ug/mL	This parameter

Convert Compare (mat) Compare (xls)
Panel View Save w/ Custom Cancel Changes Save



DILIsym PBPK Sub-Model Input Parameters Fall into Several Main Categories

- Physicochemical properties
 - Acidic/basic pKa
- Absorption
 - Saturable and linear models
- Distribution
 - Linear and non-linear plasma protein binding
 - Blood to plasma partition coefficient
 - Permeability (if permeability-limited model is selected)
 - Tissue partition coefficients
 - Transporter-mediated uptake model for liver
 - Liver partition coefficient and volume of distribution for metabolites

The screenshot shows the 'DILIsym Parameter Customization' window. At the top, there are dropdown menus for 'Group' (set to 'Drug') and 'Subgroup' (set to 'Compound W PBPK'). Below these are two tables of parameters, each with a red border around its header and first few rows.

Variable	Value	Units	
Compound W blood to plasma	1	dimensionless	This parameter
Compound W tissue distribution model	1	switch	This parameter
Compound W gut to blood	1	dimensionless	This parameter
Compound W liver to blood	1	dimensionless	This parameter
Compound W active liver uptake Vmax	0	ug/hour/kg ^{0.75}	This parameter
Compound W active liver uptake Km	1.0000e+10	ug/mL	This parameter
Compound W delay time constant (uptake induction)	0	1/hour	This parameter
Compound W uptake induction Vmax	0	1/hour	This parameter
Compound W uptake induction Km	1.0000e+10	ug/mL	This parameter
Compound W uptake induction Hill	0	dimensionless	This parameter
Compound W active liver basolateral efflux Vmax	0	ug/hour/kg ^{0.75}	This parameter
Compound W active liver basolateral efflux Km	1.0000e+10	ug/mL	This parameter
Compound W switch for calculation of tissue passive CL	1	switch	This parameter

Variable	Value	Units	
Compound W liver passive clearance	1	mL/hr/kg ^{0.75}	This parameter
Compound W apparent passive permeability	1.0000e-06	cm/sec	This parameter
Compound W liver electrogenic transport rate	0	ug/hr/kg ^{0.75} /V	This parameter
Compound W valence of ionic species	1	dimensionless	This parameter
Compound W muscle to blood	1	dimensionless	This parameter
Compound W other tissue to blood	1	dimensionless	This parameter
Compound W fraction unbound plasma	1	dimensionless	This parameter
Compound W fraction unbound correlation switch	0	dimensionless	This parameter
Compound W fu correlation 2nd-order coefficient	0	dimensionless	This parameter
Compound W fu correlation 1st-order coefficient	0	dimensionless	This parameter
Compound W fu correlation constant	0	dimensionless	This parameter
Compound W fu liver switch	0	dimensionless	This parameter
Compound W fu liver defined by the user	0	dimensionless	This parameter



DILIsym PBPK Sub-Model Input Parameters Fall into Several Main Categories

- Physicochemical properties
 - Acidic/basic pKa
- Absorption
 - Saturable and linear models
- Distribution
 - Linear and non-linear plasma protein binding
 - Blood to plasma partition coefficient
 - Permeability (if permeability-limited model is selected)
 - Tissue partition coefficients
 - Transporter-mediated uptake model for liver
 - Liver partition coefficient and volume of distribution for metabolites
- Metabolism
 - Michaelis-Menten kinetics from parent to stable metabolites in liver and gut
 - RM reactions with GSH and protein in liver

Metabolism parameters are in the “metabolite” subgroup

Variable	Value	Units
Compound W metabolite A renal clearance	0	mL/hour/kg ^{0.75}
Compound W metabolite A volume of distribution per weight	0	mL/kg
Km(Compound W metabolite A)	1.0000e+09	umol/L
Vmax(Compound W metabolite A)	0	nmol/hour/kg ^{0.75}
Compound W delay time constant (metabolite A induction)	0	1/hour
Compound W metabolite A induction Vmax	0	1/hour
Compound W metabolite A induction Km	1.0000e+10	ug/mL
Compound W metabolite A induction Hill	0	dimensionless
CL to PP activity Compound W metabolite A	1	dimensionless
ML to PP activity Compound W metabolite A	1	dimensionless
PP to PP activity Compound W metabolite A	1	dimensionless
Vmax for intestinal formation of Compound W metabolite A	0	nmol/hour/kg ^{0.75}
Km for intestinal formation of Compound W metabolite A	1.0000e+10	umol/L



DILIsym PBPK Sub-Model Input Parameters Fall into Several Main Categories

- Physicochemical properties
 - Acidic/basic pKa
- Absorption
 - Saturable and linear models
- Distribution
 - Linear and non-linear plasma protein binding
 - Blood to plasma partition coefficient
 - Permeability (if permeability-limited model is selected)
 - Tissue partition coefficients
 - Transporter-mediated uptake model for liver
 - Liver partition coefficient and volume of distribution for metabolites
- Metabolism
 - Michaelis-Menten kinetics from parent to stable metabolites in liver and gut
 - RM reactions with GSH and protein in liver
- Excretion
 - Biliary excretion (K_m and V_{max}) and renal clearance of parent and main metabolites
 - Intestinal efflux
 - Clearance of protein adducts

Variable	Value	Units
Compound W biliary excretion Vmax	0	ug/hour/kg ^{0.75}
Compound W biliary excretion Km	1.0000e+10	ug/mL
Compound W fraction recirculated	0	dimensionless
Compound W blood to plasma	1	dimensionless
Compound W tissue distribution model	1	switch
Compound W gut to blood	1	dimensionless
Compound W liver to blood	1	dimensionless
Compound W pKa 2 or pKa acid (for zwitter ion)	0	dimensionless
Compound W renal clearance	0	mL/hour/kg ^{0.75}
k(diss) - Compound W	12	1/hour
k(ge) - Compound W	12	1/hour
k(ab) - Compound W	5	1/hour
Compound W absorption from gut Vmax	0	1/hour
Compound W absorption from gut Km	1.0000e+10	mg
Compound W rate of elimination in feces	0	1/hour
k(ab, IP dose) - Compound W	12	1/hour
k(IV) - Compound W	60	1/hour
Compound W fraction unbound in enterocytes (for meta...	1	dimensionless
Compound W gut efflux Vmax	0	ug/hour/kg ^{0.75}
Compound W gut efflux Km	1.0000e+10	ug/mL

DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL

13



ADMET Predictor Predicts ADME-Tox Properties from Structure

DSSTox-ECCS - ADMET Predictor

FILE EDIT VIEW DATA CHEMISTRY TOOLS DESIGN LIBRARY HELP

Spreadsheet Controls

TILE ROWHGT PINCOL

<Mol Property> 0.00 0.00

<Mol Property> 0.00 0.00

<Mol Property> 0.00 0.00

Structure	Identifier	*Risks*	*PCB*	ADMET_Risk	ADMET_Code	S+Acidic_pKa	S+Mixed_pKa	S+Basic_pKa	DiffCoef	MlogP	S+logP	S+logD	k _a
	69210-44-2			2.500	RotB; Peff; 2C9	10.86; 6.03	None	None	0.660	2.382	3.516	2.208	
	52303-93-2			0.000		4.83	None	None	1.287	0.590	1.317	-1.060	
	108586-70-5			0.000		6.63	None	0.07	0.689	1.457	2.433	1.595	
	140947-39-3			1.558	Peff; ti	2.51	None	None	0.804	1.020	2.404	-1.182	
	75919-69-6			0.000		10.50; 2.72	None	None	0.917	0.491	1.621	0.522	
	74051-53-9			0.026	2C9	10.49; 4.74	None	-0.11	0.829	1.168	1.597	0.416	
	97404-11-0			0.272	Peff	9.37; 0.65	None	None	1.037	0.238	-0.596	-2.849	
	113849-22-2			4.707	Size; Peff; Sw; 2C9; ti	10.24; 5.53	None	1.49	0.579	3.396	4.285	2.477	
	NOCAS_44033			1.720	Size; Know; 2C9	3.86	None	None	0.583	3.339	4.942	1.547	

Compounds Classes R Tables Pairs Keys

All User Inputs PhysChem Metabolism Toxicity Simulation Descriptors User Models Risks Customize...

Ready 96 unhidden 0 hidden 0 selected

DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL

14



ADMET Predictor Can Predict Input Parameters for DILIsym PBPK Sub-Model From Structure

- Physicochemical properties

- Acidic/basic pKa ← S_Acidic/Mixed/Basic_pKa

- Absorption

- Saturable and linear models

- Distribution

- Linear and non-linear plasma protein binding ← Hum fup%
- Blood to plasma partition coefficient ← RBP
- Permeability (if permeability-limited model is selected) ← S+MDCK
- Tissue partition coefficients ← G+ Prediction
- Transporter-mediated uptake model for liver
- Liver partition coefficient and volume of distribution for metabolites ← G+ Prediction

- Metabolism

- Michaelis-Menten kinetics from parent to stable metabolites in liver and gut
- RM reactions with GSH and protein in liver

CYP1A2/2C9/2C19/2D6/3A4_
Km/Vmax
CYP HLM CLint

- Excretion

- Biliary excretion (K_m and V_{max}) and renal clearance of parent and main metabolites
- Intestinal efflux
- Clearance of protein adducts

**ADMET Predictor may
be used to predict
DILIsym toxicity inputs
in the future**

DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL

15




DILIsym Review Session Agenda


- Introduction
- IVIVE in DILIsym using ADMET Predictor
- IVIVE in DILIsym using GastroPlus
- A case study: IVIVE using GastroPlus & DILIsym to predict liver safety of an investigational drug



Exposure Profiles Generated From GastroPlus Can Be Directly Used in DILIsym



Permeability,
solubility vs. pH,
pKa(s),
logD vs. pH,
Fup,
blood:plasma
ratio, tissue Kps,
CLint, CLfilt




Quantitative Structure Activity Relationships (QSAR)

ADMET Predictor™


DILIsym Services

S+ A SIMULATIONS PLUS COMPANY



GastroPlus 9.6 Allows for Efficient Use of GastroPlus PBPK Models in Combination with DILIsym SimPops

- GastroPlus users build PBPK models within GastroPlus
- The “DILIsym” simulation mode in v9.6 allows users to select a mapping of GastroPlus outputs to DILIsym PK inputs
- All DILIsym SimPops and SimCohorts are embedded within GastroPlus so user can select option of their choice
- Exported DILIsym Specified Data Excel template is seamlessly compatible with DILIsym and contain PK outputs for **the right number of body-weight matched** rats, dogs, mice or humans
- ***This makes the manual creation of a Specified Data template unnecessary***





ADMET Predictor Can Predict Many Inputs in GastroPlus Drug Database

- With the ADMET Predictor Module, a user can automatically create a new GastroPlus drug database that contains estimates for:
 - pKa(s)
 - Human effective permeability
 - Diffusion coefficient in water
 - Human (or rat) plasma protein binding
 - Human volume of distribution
 - Human (or rat) blood:plasma concentration ratio
 - CYP metabolism kinetics
 - Log D vs. pH profile
 - Aqueous/biorelevant solubility vs. pH profile

DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL

19

Define physiochemical properties for compounds

Define the initial formulation conditions for compounds

Define the pharmacokinetic model for compounds, along with the fu,p and B:P concentration ratio

Import Structure Properties

Select experimental properties to be loaded into database instead (or in addition) of properties predicted by ADMETPredictor. GastroPlus had detected possible inputs for data that are not being predicted by ADMETPredictor and already made a selection. The inputs that were selected by GastroPlus are marked in red. Please check if these are correct and make additional corrections if desired.

If value in selected column is missing (or outside allowed range) for some compounds, it will be automatically filled in with predicted or default value. If values for solubility or logD are replaced with predicted values, corresponding pH values will be filled with predictions as well.

Compound Name:

Physico-Chemical Properties

Mwt (g/mol)

Dw (cm²/s x 10⁻⁵)

logD

pH for logD

Aq Sol (mg/mL)

pH for Aq Sol

FaSSGF (mg/mL)

FaSSIF (mg/mL)

FeSSIF (mg/mL)

Interf Tens (J/m²)

Solubility Factor

Peff (cm/s x 10⁻⁴)

Peff Source

Molecular Radius (Å)

☒ Turn ON Paracellular Permeability

Pcoemea (cm/s)

logHLC (atm-m³/mol)

Formulation Parameters

Dosage Form

Dose (mg)

Infusion Time (h)

Dose Volume (mL)

Part Radius (um)

Particle SD (um)

Particle Bins

Observed Properties

Fa (%)

FDp (%)

Fb (%)

Cmax (ug/mL)

Tmax (h)

AUC (ng-h/mL)

☒ Set 'No Batch Updates' for these records

Pharmacokinetics & Physiology

PK Model

Gut Physiology

Fup (%)

Rbp

Vc (L/kg)

Clearance

Renal CLfilt

Renal CLfilt Units

[VIVE Settings]

Value	Units	Enzyme
Vmax <input type="text" value="Use Predicted (3A4-HLM, others-rCYP)"/>	<input type="text" value="nmol/min/nmol CYP"/>	<input type="text" value="Use Predicted"/>
Km <input type="text" value="Use Predicted (3A4-HLM, others-rCYP)"/>	<input type="text" value="umol/L"/>	
CL <input type="text" value="NONE"/>	<input type="text" value="mL/min/nmol CYP"/>	

in vitro Fu (%)

Structure

☒ Draw and Display ☐ Draw and Hide ☐ Do Not Draw

Slide adapted from
Simulations Plus
GastroPlus training

DILIsym

S+ A SIMULATIONS PLUS COMPANY

Define how clearance will be estimated for compounds. Include renal clearance? Use Vmax and Km for CYP enzymes of Clint?

CONFIDENTIAL

20



User Can Refine Inputs or Use Pure Prediction to Determine Partition Coefficients

- Using the import structure with the ADMET Predictor Module will auto-populate many of the input parameters
 - If user has any further measurements for physiochemical properties (pKa, B:P, fu,p, etc), they can adjust them manually
 - No adjustments are necessary for an initial simulation
- Switching to the PK tab and selecting the PBPK model, the user can predict tissue partition coefficients
 - Number of different models available to calculate; Lukacova is generally the most trusted


The screenshot displays the GastroPlus(TM) software interface, specifically the PK Parameters tab. The 'Selected Compound' is 'DSS_Test'. The 'PK Model' is set to 'HumanAmericanMale37/0.70kg'. The 'Body Weight (kg)' is 70. The 'FPE (if fixed) [%]' is 0. The 'Intestinal' and 'Liver' checkboxes are unchecked. The 'Scale Pediatric Fup & Rbp' checkbox is checked. The 'Blood/plasma Conc Ratio' is 0.66. The 'Use Exp Plasma Fup [%]' is 10.67. The 'Use Adj Plasma Fup [%]' is 3.5687. The 'PBPK Summary' table is highlighted with a red box, showing tissue partition coefficients (Kp), clearance (CL), and other parameters for various tissues. The 'CLays (L/h)' is 0.000, 'Vss (L)' is 462.408, and 'Thalf (h)' is 0.000. The 'Calc Kps' section shows 'Perf Kp: Lukacova; Perm Kp: Poulinext' and 'Perf Fut: S+9.5; Perm FutExt: S+9.5; FutInt: S+9.5;'. The 'Observed Values' section shows 'Fa %: 0', 'CMax (µg/mL): 0', 'FDp %: 0', 'TMax (h): 0', 'F %: 0', 'AUCinf (ng-h/mL): 0', and 'Hepatic Clearance (L/h): 0'. The 'Metabolism/Transporter Scale Factors' section shows 'Enzymes' and 'Gut Transporters' with various scale factors set to 1. The 'Transfer SFs to Enz/Trans tables' and 'Liver Enzyme Turnover Rates' buttons are visible. The bottom status bar shows 'pKa Table | logD: Struct-6.1 | Diss Model: Johnson | PartSize-Sol: ON | BileSalt-Sol: ON | IDiff: ON | ConstRad: OFF | Precip: Time | Ppara: Zhim | EHC: OFF | ACAT: Conc'.

Tissue	Kp	CL	CLint	Fu/FuInt
Hepatic Artery	0.00	0.000	0.000	0.000
Lung	0.65	0.000	0.000	0.132
Arterial Supply	0.00	0.000	0.000	0.000
Venous Return	0.00	0.000	0.000	0.000
Adipose	13.04	0.000	0.000	0.007
Muscle	2.89	0.000	0.000	0.030
Liver	4.68	0.000	0.000	0.018
ACAT Gut	0.00	0.000	0.000	0.000
Spleen	2.90	0.000	0.000	0.029



GastroPlus Includes Ability to Export Excel File to be Directly Read into DILIsym

- Simulation can be run to generate necessary concentrations to be used in DILIsym
 - Selecting DILIsym allows users to choose the corresponding SimPops or SimCohorts within DILIsym GUI
- User can select which compound scaffold to use
 - Metabolites can also be specified
- Generates Excel file with relevant concentrations:
 - Blood concentration
 - Zonal liver concentration
 - Zonal sinusoidal blood concentration
 - Gut blood concentration



DILIsymServices

S+ A SIMULATIONS PLUS COMPANY


CONFIDENTIAL

22



Compound Can Be Set Up Quickly and Easily within DILIsym

- User only needs to specify data (Excel generated by GastroPlus) and input a few additional drug parameters for toxicity predictions in DILIsym:
 - Molecular weight
 - Toxicity mechanism parameters (see Training Videos at www.DILIsymHelp.com)



DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



DILIsym Review Session Agenda

- Introduction
- IVIVE in DILIsym using ADMET Predictor
- IVIVE in DILIsym using GastroPlus
- A case study: IVIVE using GastroPlus & DILIsym to predict liver safety of an investigational drug



Example Project Goal – Assess Compound X and Compound Y

- The primary goal of this simulation work within the DILIsym software was to:
 - quantitatively and mechanistically assess the liver toxicity potential of Compound X and Compound Y combining clinical and mechanistic *in vitro* data with DILIsym and GastroPlus software simulations of previous or prospective clinical dosing paradigms.





Mitochondrial Toxicity Parameters Determined for Compound Y and Compound X

- Parameter values were fit to mitochondrial data for Compound Y and Compound X
 - Electron transport chain inhibition for Compound Y
 - Both electron transport chain inhibition and uncoupling for Compound X
 - 24 hour data used
- MITOsym and DILIsym used to parameterize both compounds



DILIsym Parameter	Compound Y Value	Compound X Value	Units
Coefficient for ETC inhibition 1	38,000	Not used	μM
Coefficient for ETC Inhibition 3	0.1	4,200	μM
Max inhibitory effect for ETC inhibition 3	0.2	0.4 (max effect)	dimensionless
Uncoupler 1 effect Km	No effect	15,000	μM
Uncoupler 1 effect Vmax	No effect	22	dimensionless
Uncoupler 1 effect Hill	No effect	4	dimensionless





Oxidative Stress Parameters Determined for Compound Y and Compound X

- Parameter values were fit to 24-hour ROS data for Compound Y and Compound X
- DILIsym representation of *in vitro* environment used to parameterize both compounds
- Saturable model explored but did not lead to better fit

DILIsym Parameter	Compound Y Value	Compound X Value	Units
RNS/ROS production rate constant 1	3.4×10^{-4}	1.7×10^{-4}	mL/nmol/hr




Preclinical Data and
Simulation Results


DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

Compound Y



Compound X



CONFIDENTIAL




Compound Y Weakly Inhibits BSEP; Compound X Does Not


- Compound Y is a weak but noncompetitive/uncompetitive inhibitor of BSEP
- Compound X does not inhibit BSEP
 - No changes to V_{\max} or K_m of transporters observed over course of assay



Compound Y; $K_i = 140 \mu\text{M}$, $\alpha = 0.6$



Compound X; no inhibition





DILIsym Toxicity Parameters for Compound Y and X

Mechanism	Parameter	Unit	DILIsym Parameter Value*	
			Compound Y	Compound X
Mitochondrial Dysfunction	Coefficient for ETC inhibition 1	μM	38,000	Not used
	Coefficient for ETC Inhibition 3	μM	0.1	4,200
	Max inhibitory effect for ETC inhibition 3	dimensionless	0.2	0.4
	Uncoupler 1 effect Km	μM	No effect	15,000
	Uncoupler 1 effect Vmax	dimensionless	No effect	22
	Uncoupler 1 effect Hill	dimensionless	No effect	4
Oxidative Stress	RNS/ROS production rate constant 1	mL/nmol/hr	3.4×10^{-4}	1.7×10^{-4}
Bile Acid Transporter Inhibition	BSEP inhibition constant	μM	140	No inhibition
	BSEP inhibition alpha value	dimensionless	0.6	No inhibition
	NTCP inhibition constant	μM	No inhibition	No inhibition
	MRP4 inhibition constant	μM	40	75

*Values shown in the table for DILIsym input parameters should not be interpreted in isolation with respect to clinical implications, but rather, should be combined with exposure in DILIsym to produce simulations that have predictive and insightful value

DILIsym Services


S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



GastroPlus PBPK Model Used to Predict Liver Exposure of Compound Y and Compound X

- Data on Compound Y and Compound X pharmacokinetics not available in the literature
 - No plasma time courses available; no *in vitro* or animal studies available either
 - Data on T_{max} , Compound Y $f_{u,plasma}$ available
 - *In vitro* data on liver distribution available from intracellular data collected for this project
- Structure of each compound available online
 - QSAR modeling using ADMET Predictor and GastroPlus provided the best possible estimate of Compound Y and Compound X distribution and pharmacokinetics
- Plasma time course was estimated in GastroPlus and translated into DILIsym using “specified data” option
 - Liver:plasma partition coefficient was calculated from the cell:media ratio in the *in vitro* data and used as input into GastroPlus; the remainder of the parameters were calculated by ADMET Predictor
- Both compounds distribute significantly into the liver
 - Compound Y average cell:media was 18; Compound X average cell:media was 9



Compound Y

Compound X

DILIsymServices

A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



Compound Y PBPK Representation Calculated at Clinical Dose

- GastroPlus predictions for liver and plasma at clinical dose shown at right
 - PBPK model specific predictions shown below
 - Dose escalation was simulated

Blood/plasma Conc Ratio: 0.72



☐ Scale Pediatric Fup & Rbp

☐ Use Exp Plasma Fup [%]: 4.3

☒ Use Adj Plasma Fup [%]: 2.6893

PBPK Summary

Tissue	Kp	CL	CLint	Fut/Fulnt
Hepatic Artery	0.00	0.000	0.000	0.000
Lung	0.51	0.000	0.000	0.053
Arterial Supply	0.00	0.000	0.000	0.000
Venous Return	0.00	0.000	0.000	0.000
Adipose	5.33	0.000	0.000	0.005
Muscle	1.66	0.000	0.000	0.016
Liver	18.30	0.000	0.000	0.001
ACAT Gut	0.00	0.000	0.000	0.000
Spleen	1.69	0.000	0.000	0.016
Heart	1.89	0.000	0.000	0.014
Brain	4.24	0.000	0.000	0.006
Kidney	1.69	0.318	0.000	0.016
Skin	2.17	0.000	0.000	0.012
ReproOrg	1.70	0.000	0.000	0.016
RedMarrow	4.70	0.000	0.000	0.006
YellowMarrow	5.33	0.000	0.000	0.005
RestOfBody	1.71	0.000	0.000	0.016





Compound X PBPK Representation Calculated at Clinical Dose

- GastroPlus predictions for liver and plasma at clinical dose for 25 days shown at right
 - PBPK model specific predictions below
 - Dose escalation and alternate protocols were also simulated

☒ Scale Pediatric Fup & Rbp

Blood/plasma Conc Ratio:


☐ Use Exp Plasma Fup [%]:

☒ Use Adj Plasma Fup [%]:

?

PBPK Summary

Tissue	Kp	CL	CLint	Fut/Fulnt
Hepatic Artery	0.00	0.000	0.000	0.000
Lung	0.30	0.000	0.000	0.125
Arterial Supply	0.00	0.000	0.000	0.000
Venous Return	0.00	0.000	0.000	0.000
Adipose	1.11	0.000	0.000	0.034
Muscle	0.48	0.000	0.000	0.079
Liver	9.34	0.000	0.000	0.004
ACAT Gut	0.00	0.000	0.000	0.000
Spleen	0.51	0.000	0.000	0.074
Heart	0.60	0.000	0.000	0.063
Brain	1.10	0.000	0.000	0.034
Kidney	0.53	0.309	0.000	0.071
Skin	0.75	0.000	0.000	0.050
ReproOrg	0.54	0.000	0.000	0.070
RedMarrow	1.28	0.000	0.000	0.030
YellowMarrow	1.11	0.000	0.000	0.034
RestOfBody	0.53	0.000	0.000	0.071



Simulation Results

DILIsymServices

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL



SimPops Results Show Compound X and Compound Y to be Safe at Clinical Doses; ALT Elevations Occur at Higher Doses for Both Compounds

Compound Y

Compound X

- Neither Compound Y nor Compound X are predicted to cause toxicity at the highest clinical dose
 - Some exposure variability included in these predictions due to GastroPlus population generation
- Both Compound Y and Compound X are predicted to cause mild ALT elevations at supratherapeutic doses
 - No bilirubin elevations or Hy's Law cases occurred in simulations with Compound X
 - 2 Hy's Law cases occurred at 10x clinical dose simulations with Compound Y

	Compound	Dosing Protocol	Simulated* ALT > 3X ULN**
Compound Y	Compound Y	1X Dose, 12 weeks	0% (0/285)
		2X Dose, 12 weeks	0% (0/285)
		5X Dose, 12 weeks	0.3% (1/285)
		10X Dose, 12 weeks	10.2% (29/285)
Compound X	Compound X	1X Dose, 15 days	0% (0/285)
		2X Dose, 15 days	0% (0/285)
		5X Dose, 15 days	1.1% (3/285)
		10X Dose, 15 days	11.6% (33/285)


*The full v4A-1 SimPops (n=285) of normal healthy volunteers was used

**Upper limit of normal (ULN) in DILIsym is 40 U/L




SimPops Results Show Lack of Severe Liver Injury for Both Compound Y and Compound X at Clinical Doses


Compound Y; 1X Dose, 12 weeks




Compound Y; 2X Dose, 12 weeks




Compound Y; 5X Dose, 12 weeks




Compound Y; 10X Dose, 12 weeks




Compound X; 1X Dose




Compound X; 2X Dose



Compound X; 5X Dose



Compound X; 10X Dose



Simulation Results

DILIsymS

S+ A SIMULATIONS PLUS COMPANY


*The full v4A-1 SimPops (n=285) of normal healthy volunteers was used

**Upper limit of normal (ULN) in DILIsym is 40 U/L

CONFIDENTIAL




Focus on Hy's Law Side of eDISH Plot – Comparison of Competitors and Compound X at Clinical Doses (285 Simulated Individuals in All Cases)





Focus on Hy's Law Side of eDISH Plot – Comparison of Competitor and Compound Y at Predicted Clinical Doses (285 Simulated Individuals in All Cases)





Example Project Summary

- GastroPlus™ software, along with *in vitro* data, was used to construct PBPK representations to predict liver exposures for both compounds
- DILIsym parameters were successfully calculated from *in vitro* data for both compounds
- SimPops results show Compound X and Compound Y to be safe at projected clinical doses
- ALT elevations predicted within DILIsym at higher doses for both compounds
- SimPops results suggest that neither compound is likely to cause severe liver injury
- ***Phase IIb / III clinical trial results have subsequently confirmed the predictions for Compound Y***



Summary

- DILIsym can utilize the capabilities of ADMET Predictor and GastroPlus to move its place further ahead in the drug development pipeline
 - Can predict exposure in humans at early discovery/development stage
- ADMET Predictor uses QSAR to predict physiochemical and ADME properties which can be input into GastroPlus to predict tissue partition coefficients
- GastroPlus PBPK models easily compatible with DILIsym SimPops and SimCohorts
 - Applies to all species: human, rat, mouse, dog



Upcoming DILIsym Review Sessions

Join us for:

- **Review Session 28: “Cholangiocyte toxicity and MDR3 inhibition.” January, 2019**

DILIsym Services

S+ A SIMULATIONS PLUS COMPANY

CONFIDENTIAL